Cargando…

Anti–Ma-1 and Anti–Ma-2 Antibodies in Isolated Fatal Hypothalamitis

Lymphocytic hypothalamitis (LHT) is a rare disease characterized by pituitary dysfunction, autonomic instability, metabolic disturbances, and neuropsychiatric disorders. We report the case of a 30-year-old man found to have LHT that progressed despite treatment with methylprednisolone and intravenou...

Descripción completa

Detalles Bibliográficos
Autores principales: Bustos, Mario, Berger, Hara, Hannoush, Zeina Carolina, Ayala, Alejandro, Freire, Rochelle, Kargi, Atil Yilmaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783447/
https://www.ncbi.nlm.nih.gov/pubmed/29379898
http://dx.doi.org/10.1210/js.2017-00354
_version_ 1783295279494070272
author Bustos, Mario
Berger, Hara
Hannoush, Zeina Carolina
Ayala, Alejandro
Freire, Rochelle
Kargi, Atil Yilmaz
author_facet Bustos, Mario
Berger, Hara
Hannoush, Zeina Carolina
Ayala, Alejandro
Freire, Rochelle
Kargi, Atil Yilmaz
author_sort Bustos, Mario
collection PubMed
description Lymphocytic hypothalamitis (LHT) is a rare disease characterized by pituitary dysfunction, autonomic instability, metabolic disturbances, and neuropsychiatric disorders. We report the case of a 30-year-old man found to have LHT that progressed despite treatment with methylprednisolone and intravenous immunoglobulin (IVIG). A literature review was conducted to identify prior studies pertaining to LHT. Our patient presented with several weeks of fatigue, cold intolerance, weight loss, confusion, and headache. Laboratory tests were consistent with panhypopituitarism. Brain magnetic resonance imaging revealed an infiltrative enhancing mass in the area of the hypothalamus, and stereotactic biopsy findings showed reactive inflammatory changes. A course of hormone replacement (levothyroxine), methylprednisolone, and IVIG was initiated. The patient’s course was complicated by a fatal tonsillar herniation. Autopsy revealed LHT. The diagnosis and management of autoimmune LHT are challenging. The entity should be considered in the setting of panhypopituitarism with a hypothalamic mass. Differentiating paraneoplastic and nonparaneoplastic hypothalamitis should be established for management and prognosis. Definitive treatment remains unclear; treatment with corticosteroids should be attempted, followed by consideration of other immunosuppressive agents, such as rituximab. If a paraneoplastic syndrome is suspected, management should also be directed toward the primary tumor.
format Online
Article
Text
id pubmed-5783447
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-57834472018-01-29 Anti–Ma-1 and Anti–Ma-2 Antibodies in Isolated Fatal Hypothalamitis Bustos, Mario Berger, Hara Hannoush, Zeina Carolina Ayala, Alejandro Freire, Rochelle Kargi, Atil Yilmaz J Endocr Soc Case Reports Lymphocytic hypothalamitis (LHT) is a rare disease characterized by pituitary dysfunction, autonomic instability, metabolic disturbances, and neuropsychiatric disorders. We report the case of a 30-year-old man found to have LHT that progressed despite treatment with methylprednisolone and intravenous immunoglobulin (IVIG). A literature review was conducted to identify prior studies pertaining to LHT. Our patient presented with several weeks of fatigue, cold intolerance, weight loss, confusion, and headache. Laboratory tests were consistent with panhypopituitarism. Brain magnetic resonance imaging revealed an infiltrative enhancing mass in the area of the hypothalamus, and stereotactic biopsy findings showed reactive inflammatory changes. A course of hormone replacement (levothyroxine), methylprednisolone, and IVIG was initiated. The patient’s course was complicated by a fatal tonsillar herniation. Autopsy revealed LHT. The diagnosis and management of autoimmune LHT are challenging. The entity should be considered in the setting of panhypopituitarism with a hypothalamic mass. Differentiating paraneoplastic and nonparaneoplastic hypothalamitis should be established for management and prognosis. Definitive treatment remains unclear; treatment with corticosteroids should be attempted, followed by consideration of other immunosuppressive agents, such as rituximab. If a paraneoplastic syndrome is suspected, management should also be directed toward the primary tumor. Endocrine Society 2018-01-03 /pmc/articles/PMC5783447/ /pubmed/29379898 http://dx.doi.org/10.1210/js.2017-00354 Text en Copyright © 2018 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Reports
Bustos, Mario
Berger, Hara
Hannoush, Zeina Carolina
Ayala, Alejandro
Freire, Rochelle
Kargi, Atil Yilmaz
Anti–Ma-1 and Anti–Ma-2 Antibodies in Isolated Fatal Hypothalamitis
title Anti–Ma-1 and Anti–Ma-2 Antibodies in Isolated Fatal Hypothalamitis
title_full Anti–Ma-1 and Anti–Ma-2 Antibodies in Isolated Fatal Hypothalamitis
title_fullStr Anti–Ma-1 and Anti–Ma-2 Antibodies in Isolated Fatal Hypothalamitis
title_full_unstemmed Anti–Ma-1 and Anti–Ma-2 Antibodies in Isolated Fatal Hypothalamitis
title_short Anti–Ma-1 and Anti–Ma-2 Antibodies in Isolated Fatal Hypothalamitis
title_sort anti–ma-1 and anti–ma-2 antibodies in isolated fatal hypothalamitis
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783447/
https://www.ncbi.nlm.nih.gov/pubmed/29379898
http://dx.doi.org/10.1210/js.2017-00354
work_keys_str_mv AT bustosmario antima1andantima2antibodiesinisolatedfatalhypothalamitis
AT bergerhara antima1andantima2antibodiesinisolatedfatalhypothalamitis
AT hannoushzeinacarolina antima1andantima2antibodiesinisolatedfatalhypothalamitis
AT ayalaalejandro antima1andantima2antibodiesinisolatedfatalhypothalamitis
AT freirerochelle antima1andantima2antibodiesinisolatedfatalhypothalamitis
AT kargiatilyilmaz antima1andantima2antibodiesinisolatedfatalhypothalamitis